These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 18650570)
41. Drug resistant tuberculosis: a global public health issue. Sampathkumar P Int J Dermatol; 2008 Oct; 47(10):985-8. PubMed ID: 18986340 [No Abstract] [Full Text] [Related]
42. Totally drug-resistant tuberculosis in India: who let the djinn out? Udwadia ZF Respirology; 2012 Jul; 17(5):741-2. PubMed ID: 22564108 [No Abstract] [Full Text] [Related]
43. Management of contacts of multidrug-resistant tuberculosis patients in the European Union and European Economic Area. van der Werf MJ; Sandgren A; Manissero D Int J Tuberc Lung Dis; 2012; 16(3):426. PubMed ID: 22640458 [No Abstract] [Full Text] [Related]
44. Surveillance for MDR-TB: is there an obligation to ensure treatment for individuals identified with MDR-TB? Edginton ME; Miller DL; Burney P; El Sony AI; Lwilla FI; O'Brien R; Roldan MB; Roldan A; Srinath S Int J Tuberc Lung Dis; 2010 Sep; 14(9):1094-6. PubMed ID: 20819252 [TBL] [Abstract][Full Text] [Related]
45. [Rapidly progressing forms of pulmonary tuberculosis in adolescents]. Rusakova LI Probl Tuberk; 2001; (1):31-4. PubMed ID: 11337778 [TBL] [Abstract][Full Text] [Related]
46. [Multidrug resistant tuberculosis -- its extent, hazard and possible solutions]. Zellweger JP Rev Mal Respir; 2011 Oct; 28(8):1025-33. PubMed ID: 22099408 [TBL] [Abstract][Full Text] [Related]
48. European guidance on drug-resistant tuberculosis in children and adolescents. Gröschel MI; Seddon JA; Prabowo SA; Migliori GB; Graham SM; van den Boom M; Dara M Lancet Child Adolesc Health; 2020 Jan; 4(1):9-11. PubMed ID: 31676193 [No Abstract] [Full Text] [Related]
49. Tuberculosis care in 2013 and beyond: 20 years after the birth of the DOTS strategy. Seita A East Mediterr Health J; 2013 Mar; 19(3):211-2. PubMed ID: 23879070 [No Abstract] [Full Text] [Related]
50. Programmatic management of multidrug resistant TB. Sarin R Indian J Tuberc; 2009 Oct; 56(4):171-3. PubMed ID: 20469727 [No Abstract] [Full Text] [Related]
51. A new epidemic. Pradhan MC J Indian Med Assoc; 1996 Sep; 94(9):326-7, 333. PubMed ID: 9019075 [No Abstract] [Full Text] [Related]
52. Time to put boots on the ground: making universal access to MDR-TB treatment a reality. Keshavjee S; Farmer PE Int J Tuberc Lung Dis; 2010 Oct; 14(10):1222-5. PubMed ID: 20843411 [No Abstract] [Full Text] [Related]
53. The global threat of drug-resistant tuberculosis. Snider DE; Castro KG N Engl J Med; 1998 Jun; 338(23):1689-90. PubMed ID: 9614262 [No Abstract] [Full Text] [Related]
54. Moving forward with evidence and controversies: the challenges of MDR-TB. Chiang CY; Van Deun A; Caminero JA Int J Tuberc Lung Dis; 2006 Aug; 10(8):827. PubMed ID: 16898363 [No Abstract] [Full Text] [Related]
55. Mycobacteria: treatment approaches and mechanisms of resistance. Frothingham R J Med Liban; 2000; 48(4):248-54. PubMed ID: 11214197 [TBL] [Abstract][Full Text] [Related]
56. Drug-resistant tuberculosis of the brain in a two-year-old child. Mehta JB; Mejia E; Gallemore GH; Ramsey GF Tenn Med; 1998 Jul; 91(7):285-7. PubMed ID: 9659827 [No Abstract] [Full Text] [Related]
57. Resistance to anti-tuberculosis medications in the Horn of Africa. Ollé-Goig JE; Codina-Grau G; Martín-Casabona N Int J Tuberc Lung Dis; 2011 Mar; 15(3):414-6. PubMed ID: 21333114 [TBL] [Abstract][Full Text] [Related]
59. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Aziz MA; Wright A Clin Infect Dis; 2005 Aug; 41 Suppl 4():S258-62. PubMed ID: 16032561 [TBL] [Abstract][Full Text] [Related]
60. How are we creating fluoroquinolone-resistant tuberculosis? Bernardo J; Yew WW Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]